IDH is one of the most studied genes in glioma development, and cancers with IDH1 or IDH2 mutations produce 10–100 times more 2-HG than those with the IDH1 or IDH2 wildtype (Ward et al. 2010; Leeper et al. 2015). The gene discussed is IDH2; the disease is central nervous system cancer.